Sunitinib Malate efuefu - Gaosi oloa Tuuina atu
AASraw gaosia Cannabidiol (CBD) paʻu ma Hemp Taua Suauʻu tele!

Sunitinib Malate

fua faatatau: Category:

E taofia e le Sunitinib le faʻailoaina o telefoni feaveaʻi e ala i le faʻatatauina o le tele o receptor tyrosine kinases (RTKs). O loʻo aofia ai uma talipupuni mo le tupuʻaga o le tupu-tupu aʻe vaega (PDGF-Rs) ma vaskola endothelial tuputupu aʻe vaega taliaina (VEGFRs), lea e faia se sao i uma tumo angiogenesis ma tuma sela faʻateleina.

Faamatalaga oloa

Faʻavae Characteristics

Igoa oloa Sunitinib Malate efuefu
Numera CAS 341031-54-7
Faiga Faʻavae Molecular C22H27FN4O2
Molar vaega 398.474
Synonyms 557795-19-4;

Filemu;

Sunitinib malate efuefu;

SU11248.

Faʻaaliga Paʻu paʻu
Teuina ma Taulimaina Teu ia i le vevela potu ma alu ese mai le sili atu vevela ma susu.

 

Sunitinib Malate paʻu Faʻamatalaga

Sunitinib (maketiina o Sutent e Pfizer, ma na taʻua muamua o le SU11248) o se tautala, laʻititi-mole, tele-faʻataʻotoina receptor tyrosine kinase (RTK) taofia na faʻamaonia e le FDA mo le togafitia o le sela sela carcinoma (RCC) ma imatinib -resistant gastrointestinal stromal tumom (GIST) ia Ianuari 26, 2006. Sunitinib o le muamua kanesa fualaʻau faʻamaonia i le taimi e tasi mo faʻailoga eseese e lua.

 

Sunitinib Malate paula Faʻavae o gaioiga

Sunitinib taofi le faʻaaogaina o le telefoni e ala i le faʻatatauina o le tele o receptor tyrosine kinases (RTKs).

E aofia ai uma talipupuni mo lapisi-mafua tuputupu aʻe mafuaʻaga (PDGF-Rs) ma vascular endothelial tuputupu aʻe vaega taliaina (VEGFRs), lea ei ai se sao i uma tuma angiogenesis ma tuma sela faʻateleina. O le taofi faʻatasi o nei taulaʻi o le mea lea e faʻaititia ai le vascularization o le tuma ma amata ai le kanesa o le apoptosis, ma mafua ai ona faʻaitiitia le tuma.

E taofia foi e le Sunitinib le CD117 (c-KIT), [2] o le receptor tyrosine kinase na (pe a le faʻagaoioia le talafeagai e ala i fesuiaiga) aveina le tele o gastrointestinal stromal cell tumors. i le C-KIT latou te teteʻe ai i le imatinib, poʻo ai e le mafai onosaʻi le vailaʻau.

 

Sunitinib Malate efuefu Talosaga

 Gastrointestinal stromal tumo

Pei ole RCC, GIST e le masani ona tali atu ile tulaga masani ole chemotherapy poʻo le radiation. Imatinib o le muamua kanesa sooupu faamaonia lelei mo metastatic GIST ma fai ma sui o se tele atinae i le togafitiga o lenei seasea ae luitauina faamai.

 

 Menusioma

Sunitinib o loʻo suʻesuʻeina mo togafitiga o le meningioma e fesoʻotaʻi ma le neurofibromatosis.

 

 Tumora neuroendocrine tumors

Ia Novema 2010, na maua ai e Sutent le faʻamaoniga mai le Komisi a Europa mo le togafitia o le 'le mafaʻafilemuina poʻo metastatic, eseʻese faʻafuaseʻi neuroendocrine tuma ma faʻasolosolo faʻamaʻi i tagata matutua'.

 

 Toto kanesa o le sela

Sunitinib ua faʻamaonia mo togafitiga o metastatic RCC. Isi togafitiga togafitiga i lenei nofoaga o pazopanib (Votrient), sorafenib (Nexavar), temsirolimus (Torisel), interleukin-2 (Proleukin), everolimus (Afinitor), bevacizumab (Avastin), ma aldesleukin.

 

Sunitinib Malate efuefu Aafiaga Itu & Lapataiga

Sunitinib leaga mea tutupu o loʻo manatu e mafai ona faʻatonutonuina ma le aʻafiaga o mea ogaoga mea leaga na maualalo.

O mea masani e tutupu faʻatele e fesoʻotaʻi ma sunitinib togafitiga o le lelava, manava manava, niniva, anorexia, toto maualuga, o le paʻu samasama discoloration, lima-vae paʻu tali atu, ma stomatitis. I le placebo-pulea Phase III GIST suʻesuʻega, leaga mea tutupu na tupu soo i sunitinib nai lo placebo aofia manava, anorexia, paʻu lanu, mucositis / stomatitis, asthenia, suia tofo, ma manava.

O toʻaga e tatau ona faʻaititia i le 50% o tagata mamaʻi na aʻoaʻoina i le RCC ina ia mafai ai ona faʻatonutonuina le oona o lenei sui.

Matuia (vasega 3 poʻo le 4) mea leaga na tutupu i le ≤10% o tagata mamaʻi ma aofia ai le toto maualuga, lelava, astenia, manava tatā, ma chemotherapy-faʻaosofia acral erythema. Lab abnormalities fesoʻotaʻi ma sunitinib togafitiga aofia lipase, amylase, neutrophils, lymphocytes, ma platelets. Hypothyroidism ma feliuaʻi erythrocytosis ua fesoʻotaʻi foʻi ma sunitinib.

 

Tusitaiala

[1] US Food and Drug Administration (2006). "Faʻamaonia e le FDA ni togafitiga fou mo le kanesa o le manava ma le kanesa".

[2] Hartmann JT, Kanz L (Novema 2008). "Sunitinib ma faavaitaimi lauulu depigmentation ona o le tumau c-KIT taofiofia". Arch Dermatol. 144 (11): 1525–6. faia: 10.1001 / archderm.144.11.1525. PMID 19015436. Faamaumau mai le amataga i le 2011-07-25.

[3] Quek R, George S (Fepuari 2009). "Gastrointestinal stromal tumo: o le aotelega o togafitiga" Hematol Oncol Falemai North Am. 23 (1): 69–78, viii. faia: 10.1016 / j.hoc.2008.11.006. PMID 19248971.

[4] Blay JY, Reichardt P (Iuni 2009). "Advanced gastrointestinal stromal tumo i Europa: o se toe iloiloga o faʻafouga togafitiga faʻutua". Tomai Rev Anticancer Ther. 9 (6): 831–8. faia: 10.1586 / vaitaimi.09.34. PMID 19496720. S2CID 23601578.

[5] Gan HK, Seruga B, Knox JJ (Iuni 2009). "Sunitinib i mautu tuma". Tomai Faʻapitoa Opin Investig. 18 (6): 821–34. faia: 10.1517 / 13543780902980171. PMID 19453268. S2CID 25353839.

[6] "Faʻamatalaina faʻamatalaga mo Sutent (sunitinib malate paʻu)". Pfizer, Inc., Niu Ioka NY.